They authors uncovered the central role of endothelin 1 and point to the potential value of endothelin receptor antagonists to suppress the outgrowth of resistant cells and maintain and improve BRAF inhibitor treatment response.
In one example, the far-red real-time viability probe DRAQ7 was combined with Fucci technology to monitor cell cycle progression and cell fate (death) in 72h (ca. 3 rounds of divisions) time-lapse imaging procedure that showed a high degree of hetrogeneity cell-by-cell in response even within a single cell line.
WHERE TO BUY
Reference:
Smith et al. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Mol Med. June 12, 2017 e201607156
Reference:
Smith et al. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Mol Med. June 12, 2017 e201607156
No comments :
Post a Comment